2016
Characterizing Patients with Very-Low-Level HIV Viremia: A Community-Based Study
Helou E, Shenoi S, Kyriakides T, Landry ML, Kozal M, Barakat LA. Characterizing Patients with Very-Low-Level HIV Viremia: A Community-Based Study. Journal Of The International Association Of Providers Of AIDS Care (JIAPAC) 2016, 16: 261-266. PMID: 27903948, PMCID: PMC5423832, DOI: 10.1177/2325957416680028.Peer-Reviewed Original ResearchConceptsVirologic failureViral load levelsPill burdenAlcohol useHuman immunodeficiency virus (HIV) careLow-level HIV viremiaUndetectable viral load levelsAntiretroviral regimen changesAntiretroviral therapy changesExperienced virologic failureLow-level viremiaIntravenous drug useSubset of patientsFrequent clinic visitsPoor clinical outcomePossible risk factorsHepatitis C virusHIV viremiaMore comorbiditiesNonfailure groupVirologic suppressionVirological failureCD4 countConsecutive chartsClinic visits
2012
Predictive value of HIV‐1 replication capacity and phenotypic susceptibility scores in antiretroviral treatment‐experienced patients
Bedimo R, Kyriakides T, Brown S, Weidler J, Lie Y, Coakley E, Holodniy M. Predictive value of HIV‐1 replication capacity and phenotypic susceptibility scores in antiretroviral treatment‐experienced patients. HIV Medicine 2012, 13: 345-351. PMID: 22276745, DOI: 10.1111/j.1468-1293.2011.00981.x.Peer-Reviewed Original ResearchConceptsCD4 cell countViral load changesWeek 12Replication capacityPredictive valueCell countCD4 cell count responseHIV-1 replication capacityAntiretroviral treatment responseHIV replication capacityImmediate salvage therapyPhenotypic susceptibility scoresDrug-free periodPhenotypic resistance testingCell count responseAdditional predictive valueMultivariate regression analysisTreatment reinitiationSalvage therapyWeek 24ARV therapyViral loadPrognostic valueARV treatmentAntiretroviral trials
2010
Connection Domain Mutations in Treatment-Experienced Patients in the OPTIMA Trial
Dau B, Ayers D, Singer J, Harrigan PR, Brown S, Kyriakides T, Cameron DW, Angus B, Holodniy M. Connection Domain Mutations in Treatment-Experienced Patients in the OPTIMA Trial. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2010, 54: 160-166. PMID: 20130473, DOI: 10.1097/qai.0b013e3181cbd235.Peer-Reviewed Original ResearchConceptsTreatment-naive populationTreatment-experienced patientsCD mutationsTreatment-experienced populationsHIV viral loadConnection domainConnection domain mutationsOPTIMA trialVirologic outcomesVirologic responseARV regimenARV therapyViral loadAntiretroviral drugsAntiretroviral trialsUnivariate analysisDiminished responseFrequency of mutationsMultivariate analysisPatientsReduced susceptibilityA371VDomain mutationsResistance phenotypeTrials
2007
Evolution of Genotypic Resistance Algorithms and Their Impact on the Interpretation of Clinical Trials: An OPTIMA Trial Substudy
Desai S, Kyriakides T, Holodniy M, Al-Salman J, Griffith B, Kozal M. Evolution of Genotypic Resistance Algorithms and Their Impact on the Interpretation of Clinical Trials: An OPTIMA Trial Substudy. HIV Research & Clinical Practice 2007, 8: 293-302. PMID: 17956830, DOI: 10.1310/hct0805-293.Peer-Reviewed Original ResearchConceptsLong-term clinical trialsGenotypic resistance algorithmsClinical trialsDisease progressionHIV disease progression ratesHIV-1 pol sequencesHIV disease progressionDisease progression rateResistance algorithmsVirologic responseDrug comparisonsProgression rateVirtual phenotypeGenotypic algorithmsPol sequencesPatientsDrug resistanceResistance interpretationTrialsProgressionDrugsExpected ratesViral sequencesFirst eventSimilar time
2001
Development and Application of a Genotypic AZT Resistance Assay: Quantitative Assessment of the Resistance Profile of Clinical Samples and the Relative Predictive Ability of a Resistance Index.
Kyriakides TC, Heimer RR. Development and Application of a Genotypic AZT Resistance Assay: Quantitative Assessment of the Resistance Profile of Clinical Samples and the Relative Predictive Ability of a Resistance Index. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2001, 28: 211. PMID: 11694826, DOI: 10.1097/00042560-200111010-00002.Peer-Reviewed Original ResearchConceptsViral loadCD4 countResistance indexAZT resistanceResistance profilesBaseline viral loadHIV disease progressionLigase chain reaction assayMonths of treatmentWild-type HIV-1Resistance assaysAntiretroviral therapyDisease progressionSurrogate markerChain reaction assaysHIV-1PatientsAZTPredictive abilityClinical samplesReaction assaysCountAssaysRelative predictive abilityFurther support
1999
HIV-1 Transmission in Injection Paraphernalia: Heating Drug Solutions May Inactivate HIV-1
Clatts M, Heimer R, Abdala N, Goldsamt L, Sotheran J, Anderson K, Gallo T, Hoffer L, Luciano P, Kyriakides T. HIV-1 Transmission in Injection Paraphernalia: Heating Drug Solutions May Inactivate HIV-1. JAIDS Journal Of Acquired Immune Deficiency Syndromes 1999, 22: 194-199. PMID: 10843535, DOI: 10.1097/00126334-199910010-00013.Peer-Reviewed Original Research